EGFR and head and neck cancer: Even though there is no clinical study ongoing utilizing Panitumumab-IR700, the IR700 conjugated anti-EGFR PIT Cetuximab Salotarocan is currently under investigation in phase I/II studies for EGFR expressing advanced solid tumors in combination with anti-PD1 treatment, as well as phase III studies for head and neck cancer (NCT03769506).